State Street's XLV and iShares' IXJ offer distinct paths for healthcare exposure, with XLV leading in cost efficiency and recent returns while IXJ provides broader global diversification.
Compared with iShares IXJ in a neutral ETF comparison article; no new catalyst.
Compared with State Street XLV in a neutral ETF comparison article; no new catalyst.
Mentioned as a top holding of both healthcare ETFs; no specific company news.
Mentioned as a top holding of both healthcare ETFs; no specific company news.
Mentioned as a top holding of both healthcare ETFs; no specific company news.
Investors weighing healthcare exposure face a choice between the domestic focus of the State Street XLV and the global reach of the iShares IXJ. While both funds share top holdings like Eli Lilly, Johnson & Johnson, and AbbVie, they differ significantly in expense ratios and historical performance. XLV currently offers lower costs and higher recent returns, while IXJ provides broader international diversification.
The primary difference is geographic scope; XLV focuses exclusively on U.S.-based healthcare stocks within the S&P 500, while IXJ is a global fund that includes international equities.
XLV is more cost-effective, charging an expense ratio of 0.08% compared to the 0.38% charged by IXJ.